Woodcock Attributes Aduhelm Approval Controversy To ‘Process Problems’
Executive Summary
US FDA’s approval after a near-unanimous advisory committee vote against Biogen’s Alzheimer’s drug is central to many critics’ arguments, but the acting commissioner says that panel did not vote on the issue of accelerated approval, and that airing of internal agency disagreements could have influenced committee members.
You may also be interested in...
US FDA Communication Ahead Of Major Actions Could Counter Misinformation, Ex-Official Says
Instead of waiting until after regulatory events like COVID boosters and Aduhelm, FDA should describe its decision-making process along the way to help restore public faith in the agency, former deputy commissioner Josh Sharfstein says.
Aduhelm Invades Senate Committee’s COVID-19 Hearing
Woodcock again defends the decision, saying Congress intended accelerated approval for those situations.
And Then There Were Three: Woodcock Offers Another Explanation For Aduhelm’s Labeling Fiasco
Acting US FDA Commissioner says it is standard for the Office of Neuroscience to issue broad labels like the one originally granted to Biogen’s new Alzheimer’s drug, but the agency declined to answer follow-up questions on such a policy. Woodcock continued to defend Aduhelm’s accelerated approval but conceded that the process might have been improved in an unusually tense public appearance.